ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Vendor deposits | NaN | 14,484 | 169,363 | 98,234 |
| Cash | 302,660 | 101,778 | 527,978 | 72,086 |
| Prepaid expenses and other current assets | 439,563 | 231,639 | 298,192 | 378,749 |
| Total current assets | 742,223 | 347,901 | 995,533 | 549,069 |
| Vendor deposit | NaN | NaN | NaN | 69,477 |
| In-process research and development | NaN | NaN | NaN | 18,647,903 |
| Deferred offering costs | NaN | NaN | 44,727 | 374,662 |
| Total assets | 742,223 | 347,901 | 1,040,260 | 19,641,111 |
| Accounts payable | 10,235,276 | 10,123,391 | 9,805,129 | 9,774,230 |
| Accrued expenses and other current liabilities | 3,303,242 | 2,611,296 | 2,960,698 | 2,915,448 |
| Convertible notes payable at fair value | 1,200,000 | NaN | NaN | NaN |
| Warrant liabilities | 128,000 | NaN | NaN | NaN |
| Total current liabilities | 14,866,518 | 12,734,687 | 12,765,827 | 12,689,678 |
| Deferred tax liability | NaN | NaN | NaN | 851,659 |
| Total liabilities | 14,866,518 | 12,734,687 | 12,765,827 | 13,541,337 |
| Preferred stock | 1 | 1 | 1 | 1 |
| Preferred stock-Series APreferred Stock | NaN | NaN | NaN | 0 |
| Common stock | 809 | 809 | 809 | 487 |
| Additional paid-in-capital | 125,260,381 | 125,204,509 | 125,187,156 | 123,207,260 |
| Accumulated deficit | -139,378,318 | -137,584,937 | -136,906,365 | -117,100,806 |
| Treasury stock, at cost, 7 shares at march 31, 2026 and december 31, 2025 | 7,168 | 7,168 | 7,168 | 7,168 |
| Total stockholders deficit | -14,124,295 | -12,386,786 | -11,725,567 | 6,099,774 |
| Total liabilities and stockholders deficit | 742,223 | 347,901 | 1,040,260 | 19,641,111 |